Mycophenolic
acid (MPA) is an immunosuppressive agent used to prevent rejection in organ
transplantation.
We recently have published this pathway summary in the Pharmacogenetics and Genomics Journal.
The article and included figure
describe the metabolism of MPA and its prodrug mycophenolate mofetil. MPA is a
noncompetitive, selective and reversible inhibitor of inosine monophosphate
dehydrogenase (IMPDH). The pharmacodynamic section shows several mechanisms of
actions.
Interindividual variability in the MPA exposure levels within and among populations has been observed. The article summarizes studies reporting the clinical association of genetic variants in PK and PD genes with MPA exposure and risk of rejection or GI toxicity (one of the major toxicities associated with MPA).
Find out more...
View the Mycophenolic acid pathway on PharmGKB.
Read the publication:
Lamba V, Sangkuhl K, Sanghavi K, Fish A, Altman RB, Klein TE.
Pharmacogenet Genomics. 2013 Nov 11.
PMID: 24220207
View all pathways on PharmGKB.
